Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029 M. Surdo, C. Alteri, M.C. Puertas, P. Saccomandi,

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Circumcision and penile human papillomavirus prevalence in human immunodeficiency virus-infected men: heterosexual and men who have sex with men M.P.

Twelve years of dengue surveillance in Belgian travellers and significant increases in the number of cases in 2010 and 2013 J. Verschueren, L. Cnops,

Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract A. Torres-Cornejo, O.J.

Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines.

L. Boyanova Clinical Microbiology and Infection

I.J. Schalk Clinical Microbiology and Infection

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

Migrant health—a cause for concern?

Association of CD209L tandem repeats polymorphism with susceptibility to human immunodeficiency virus-1 infection, disease progression, and treatment.

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

Refugee crisis and re-emergence of forgotten infections in Europe

R. Cantón Clinical Microbiology and Infection

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A M. Surdo, C. Alteri, M.C. Puertas, P. Saccomandi,

The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients M.M. Santoro, D. Armenia, L. Fabeni,

Dermatitis by Dermatophilus congolensis

Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008–2013 L.E.B. Nabarro, R.A. Lever, M. Armstrong,

Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice? T. Coenye, D. Goeres, F. Van Bambeke, T. Bjarnsholt

Prevalence of Toscana virus antibodies in residents of Croatia

H. Adibhesami, M. Douraghi, M. Rahbar, A. Abdollahi

Vector control: a cornerstone in the malaria elimination campaign

Do we need new antibiotics?

Update and new insights in encephalitis

Unexpectedly high prevalence of Treponema pallidum infection in the oral cavity of human immunodeficiency virus-infected patients with early syphilis.

E.C. Böttger Clinical Microbiology and Infection

Isospora belli Clinical Microbiology and Infection

C. Fabrizio, A. Procopio Clinical Microbiology and Infection

Next-generation sequencing technology in clinical virology

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Elements of design: the knowledge on which we build

V Duque, ÁA. Holguín, M. Silvestre, J. GonzÁAlez-Lahoz, V. Soriano

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

Tigecycline-induced inhibition of mitochondrial DNA translation may cause lethal mitochondrial dysfunction in humans S.J. Vandecasteele, S. Seneca, J.

Previously unknown species of Aspergillus

Sexually acquired Zika virus: a systematic review

Systematic review of antibiotic consumption in acute care hospitals

Update on antifungal resistance in Aspergillus and Candida

Abstracts cont. Clinical Microbiology and Infection

Testing patients with non-specific symptoms for antibodies against Borrelia burgdorferi sensu lato does not provide useful clinical information about.

Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection E. Knops, E. Heger Clinical Microbiology.

C. Tamalet, P. Colson, E. Decroly, C. Dhiver, I. Ravaux, A. Stein, D

Reducing antibiotic use in influenza: challenges and rewards

Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy L. Boglione,

F. Ceccherini-Silberstein, V. Cento, V. Calvez, C.-F. Perno

S. M. Bartsch, J. A. McKinnell, L. E. Mueller, L. G. Miller, S. K

Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS M. Rybicka,

An after-hours clinical liaison blood culture service—is it worth it?

Increasing numbers of hospitalizations and deaths with mention of Clostridium difficile infection, north-eastern Italy, 2008–2013 U. Fedeli, E. Schievano,

HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients N. Gianotti,

Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis

Overview of cefixime use in community-acquired infections

M.T. Pérez-Rodríguez, A. Sousa, P. Martínez-Cueto, A. Ocampo

Control of human cytomegalovirus infection in patients infected with human immunodeficiency virus by high levels of specific CD8+ T-cells D. Lilleri,

Survival of rhinoviruses on human fingers

The atypical pneumonias: clinical diagnosis and importance

Abstracts Clinical Microbiology and Infection

Virology: a scientific discipline facing new challenges

R. Khatib, G. Simeunovic, M. Sharma, M. G. Fakih, L. B. Johnson, L

B.A. Cunha Clinical Microbiology and Infection

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

CMI readers' survey Clinical Microbiology and Infection

Rajko Saletinger, Mario Poljak, Franc Strle

The future of diagnostic bacteriology

Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection A. Russo, M. Falcone, M. Fantoni, R. Murri,

Presentation transcript:

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029 M. Surdo, C. Alteri, M.C. Puertas, P. Saccomandi, L. Parrotta, L. Swenson, D. Chapman, G. Costa, A. Artese, E. Balestra, S. Aquaro, S. Alcaro, M. Lewis, B. Clotet, R. Harrigan, H. Valdez, V. Svicher, C.F. Perno, J. Martinez-Picado, F. Ceccherini-Silberstein Clinical Microbiology and Infection Volume 21, Issue 1, Pages 103.e1-103.e6 (January 2015) DOI: 10.1016/j.cmi.2014.08.002 Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 In vitro and in vivo virological response to maraviroc. (A) Dose–response curves for maraviroc (MVC)-dependent inhibition of R5+/X4, R5/X4, R5/X4+ and X4 human immunodeficiency virus type 1 (HIV-1) strains in primary peripheral blood mononuclear cells. Dots represent the percentage of inhibition at 0.02, 0.2, 2, 20, 200, 500, 1000 and 10 000 nM MVC concentration for each virus. (B) Virological response in HIV-1-infected subjects with weighted optimized background therapy susceptibility score of <1 receiving antiretroviral therapy including MVC 300 mg twice daily. Clinical Microbiology and Infection 2015 21, 103.e1-103.e6DOI: (10.1016/j.cmi.2014.08.002) Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions